1. Clinical Overview of Cartalax

Molecule: Cartalax (Ala-Glu-Asp) is a synthetic tripeptide bioregulator derived from bovine cartilage tissue, developed by the St. Petersburg Institute of Bioregulation and Gerontology under the direction of Prof. Vladimir Khavinson. It is a tissue-specific peptide that exerts targeted regulatory activity in chondrocytes, extracellular matrix (ECM) tissue, and articular cartilage.

Key Properties

Tissue-specific chondroprotective bioregulator
Promotes chondrocyte proliferation and ECM anabolism
Epigenetic modulator — activates cartilage-specific gene expression
Anti-inflammatory activity within synovial and pericartilaginous tissue
Inhibits catabolic matrix metalloproteinase (MMP) activity
Supports collagen type II and proteoglycan synthesis
Well-tolerated with favorable short- and long-term safety profile

Primary Roles

Cartilage preservation and regenerative support
Chondrocyte viability and proliferation
Joint pain reduction and functional restoration
Post-surgical and post-injury articular recovery
Anti-aging connective tissue maintenance
Intervertebral disc and spinal cartilage support

2. Mechanisms of Action

2.1 Epigenetic Regulation of Chondrocyte Gene Expression

Cartalax operates as a peptide bioregulator through direct interaction with chromatin, specifically influencing histone acetylation and DNA methylation states to restore or enhance expression of cartilage-specific genes. Research from the Khavinson laboratory demonstrates that short peptide bioregulators bind directly to DNA promoter sequences, activating transcription of target tissue genes — including those encoding COL2A1 (collagen type II), aggrecan, and SOX9.

Clinical significance: Unlike NSAIDs or corticosteroids that suppress symptoms without addressing tissue biology, Cartalax acts upstream at the gene regulation level to promote regenerative chondrocyte function rather than simply masking inflammation.

2.2 Chondrocyte Proliferation & Anabolic Matrix Synthesis

Cartalax directly stimulates chondrocyte mitotic activity and biosynthetic output, leading to:

Increased production of collagen type II — the primary structural collagen of articular cartilage
Enhanced synthesis of proteoglycans (aggrecan, versican) that maintain cartilage hydration and compressive load tolerance
Upregulation of glycosaminoglycans (GAGs), including chondroitin sulfate and keratan sulfate
Improved chondrocyte density within the cartilage matrix

2.3 Anti-Inflammatory & MMP Inhibition

Cartalax modulates the inflammatory microenvironment within synovial and periarticular tissue by:

Downregulating pro-inflammatory cytokines: IL-1β, IL-6, TNF-α
Inhibiting matrix metalloproteinases MMP-1, MMP-3, and MMP-13 — key mediators of cartilage degradation in osteoarthritis
Reducing NF-κB pathway activation in inflamed synoviocytes
Shifting macrophage polarization toward the anti-inflammatory M2 phenotype in periarticular tissue

Clinical significance: By simultaneously stimulating anabolic matrix production and suppressing catabolic enzyme activity, Cartalax creates a favorable anabolic-to-catabolic ratio in joint tissue — the critical determinant of cartilage net balance over time.

2.4 Chondrocyte Apoptosis Suppression

In degenerative joint conditions, chondrocyte apoptosis is a primary driver of irreversible cartilage loss. Cartalax has demonstrated antiapoptotic activity via:

Upregulation of Bcl-2 (anti-apoptotic) and suppression of Bax (pro-apoptotic) expression
Reduction of caspase-3 activation under inflammatory stress conditions
Protection of mitochondrial membrane integrity in chondrocytes exposed to oxidative stress

2.5 Subchondral Bone & Synovial Membrane Influence

Emerging evidence suggests Cartalax also exerts regulatory influence on adjacent joint structures, including normalization of subchondral bone remodeling dynamics and reduction of synovial hypertrophy — both of which contribute to improved biomechanical joint function and reduced pain load in osteoarthritic joints.

3. Evidence-Based Clinical Applications

3.1 Osteoarthritis (OA) — Primary Indication

Cartalax is most extensively studied and applied in osteoarthritis management, with clinical and preclinical data supporting:

Reduction in joint pain scores (VAS) across knee, hip, and small joint OA
Improvements in functional mobility and range of motion
Slowing of radiographic cartilage space narrowing over multi-year follow-up in Russian longitudinal studies
Reduction in NSAID and analgesic reliance in actively treated cohorts

Clinical note: Cartalax is often considered a foundational peptide for integrative OA protocols, frequently stacked with BPC-157, TB-500, or hyaluronic acid to address multiple pathophysiological domains simultaneously.

3.2 Post-Surgical Joint Recovery

Following arthroscopic procedures, meniscal repair, ACL reconstruction, or joint replacement, Cartalax supports accelerated recovery through:

Enhanced chondrocyte repopulation at resurfacing sites
Reduced post-operative synovial inflammation
Promotion of collagen scaffold formation in healing tissue
Shorter time to functional weight-bearing and mobility restoration

3.3 Athletic & Sports Medicine Applications

In high-demand athletic populations, repetitive joint loading and microtrauma create a chronic low-grade catabolic environment in cartilage. Cartalax is applied for:

Preventive cartilage maintenance in high-impact sport athletes
Acute injury recovery (ligament, tendon-adjacent cartilage damage)
Return-to-play acceleration following joint injury
Off-season joint restoration cycling

3.4 Intervertebral Disc & Spinal Cartilage Degeneration

The nucleus pulposus of intervertebral discs shares key biological characteristics with articular cartilage, including reliance on proteoglycan-rich ECM for hydration and load distribution. Cartalax shows potential applicability in:

Discogenic back pain and early disc degeneration
Facet joint arthrosis
Cervical and lumbar spondylosis management

3.5 Longevity & Age-Related Connective Tissue Maintenance

As part of comprehensive longevity peptide protocols, Cartalax addresses the progressive age-related decline in chondrocyte biosynthetic capacity. Regular cycling in patients aged 45+ may support:

Preservation of articular cartilage thickness
Maintenance of joint fluid viscosity and lubrication
Reduced risk of advanced OA progression
Integration with systemic peptide anti-aging protocols (Epitalon, Thymalin, Vilon)

3.6 Rheumatoid & Inflammatory Arthropathies (Adjunctive)

While not a primary disease-modifying agent in autoimmune arthritis, Cartalax may serve an adjunctive role in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis by:

Protecting residual cartilage from inflammatory destruction
Supporting joint tissue repair during remission phases
Complementing DMARDs and biologics without known pharmacological interference

Note: Use in active autoimmune flares should be approached conservatively and only under direct rheumatological supervision.

4. Administration & Dosing Protocols

Cartalax is compounded and administered primarily via subcutaneous injection and oral capsules. Injectable administration remains the best-studied route based on the original Khavinson bioregulator research. Oral formulations offer a practical maintenance option with reduced but clinically meaningful bioavailability.

4.1 Subcutaneous Injection (Primary / Most Studied Route)

Standard Dose: 5–10 mg per injection session

Frequency: Daily or every other day × 10–20 sessions per cycle

Injection site: Subcutaneous — abdomen, lateral thigh, or upper arm

Cycle duration: 10–20 days for acute/therapeutic protocols; 10-day cycles repeated 2–3× per year for maintenance

Reconstitution: Lyophilized powder reconstituted in bacteriostatic water or sterile saline; use within 28 days when refrigerated

4.2 Oral Capsule Administration

Dose: 10–20 mg per day, taken with or without food

Timing: Morning dosing preferred; may split into two doses (AM/PM) at higher end of range

Cycle duration: 30–60 days per cycle; repeat 2–3× per year

Note: Oral bioavailability is lower than subcutaneous; dosing is adjusted proportionally. Suitable for maintenance, prevention, and patients who prefer non-injectable routes.

4.3 Condition-Specific Dosing Protocols

Osteoarthritis (Mild to Moderate)

SQ: 5 mg every other day × 10 injections per cycle; 2–3 cycles/year
Oral: 10 mg daily × 30–45 days; 2–3 cycles/year
Consider concurrent oral supplementation with collagen type II, glucosamine, and chondroitin

Osteoarthritis (Moderate to Severe)

SQ: 10 mg daily × 10–20 sessions; repeat every 3–4 months
May be stacked with BPC-157, TB-500, or platelet-rich plasma (PRP) injections for synergistic tissue repair
Consider combination with intra-articular hyaluronic acid for joint lubrication support

Post-Surgical Recovery

SQ: 5–10 mg daily beginning 2–4 weeks post-operatively (after wound healing is established)
Duration: 10–20 sessions; may repeat once 6–8 weeks later
Often stacked with BPC-157 for synergistic collagen remodeling effects

Athletic Maintenance & Prevention

Oral: 10 mg daily × 30 days; 2× per year (off-season or planned rest periods)
SQ option: 5 mg every other day × 10 sessions annually

Longevity / Anti-Aging Protocol

Oral: 10 mg daily × 30 days; 1–2× per year as part of broader peptide bioregulator cycling
Often integrated with Epitalon, Thymalin, and Vilon in comprehensive tissue-targeted protocols

4.4 Stacking Considerations

Cartalax is commonly combined with complementary peptides and agents for enhanced clinical effect:

BPC-157 — synergistic collagen synthesis and tendon/ligament repair; excellent pairing for post-surgical and sports injury protocols
TB-500 (Thymosin Beta-4) — promotes actin polymerization, tissue remodeling, and anti-inflammatory signaling
GHK-Cu — copper peptide with potent anti-inflammatory and ECM remodeling properties; useful in systemic connective tissue programs
Epitalon — telomerase activation and anti-aging; commonly combined in comprehensive Khavinson longevity protocols
PRP / PRF — growth factor-rich biologics that complement Cartalax's chondroprotective effects; synergistic intra-articular or periarticular use
Hyaluronic acid (oral or IA) — joint lubrication and synovial fluid viscosity support

4.5 Duration & Cycling

Acute therapeutic: 10–20 day injectable course; repeat as needed based on clinical response
Maintenance cycling: 2–3 courses per year (injectable or oral)
Long-term monitoring: Clinical reassessment at 6-month intervals; imaging (X-ray, MRI) annually in advanced OA cases

5. Clinical Decision Trees

Decision Tree 1 — Is Cartalax Appropriate?

Joint pain with confirmed or suspected cartilage involvement? → Yes

Osteoarthritis (any grade)? → Strong Yes

Post-surgical joint recovery? → Yes

Athletic joint maintenance or injury recovery? → Yes

Age-related connective tissue decline (45+)? → Yes

Intervertebral disc or spinal cartilage involvement? → Consider

Active autoimmune arthritis (RA, PsA)? → Use adjunctively / consult rheumatology

Active malignancy? → Contraindicated

Decision Tree 2 — Route & Dose Selection

Active OA / acute pain → SQ 10 mg daily × 10–20 sessions

Mild OA / early degeneration → SQ 5 mg EOD × 10 sessions · or Oral 10 mg/day × 30 days

Post-surgical recovery → SQ 5–10 mg daily × 10–20 sessions

Athletic maintenance → Oral 10 mg/day × 30 days · 2× per year

Longevity / anti-aging → Oral 10 mg/day × 30 days · 1–2× per year

Patient prefers non-injectable → Oral 10–20 mg/day × 30–60 days

Decision Tree 3 — Stacking Strategy

OA + systemic inflammation → Add BPC-157 + GHK-Cu

Post-surgical / soft tissue involvement → Add BPC-157 + TB-500

Athletic injury recovery → Add TB-500 + BPC-157

Longevity program → Add Epitalon + Thymalin

Intra-articular support needed → Add PRP/PRF ± hyaluronic acid

6. Safety, Contraindications & Monitoring

6.1 Contraindications

Pregnancy or breastfeeding
Active malignancy or history of cartilage/connective tissue cancer (theoretical proliferative concern)
Hypersensitivity to any peptide component or bovine-derived products
Active systemic infection (defer treatment until resolved)
Severe hepatic or renal impairment (limited data; use with caution)

6.2 Potential Side Effects

Cartalax has a favorable tolerability profile in published literature. Side effects are generally mild and transient:

Injection site reactions — mild erythema, transient tenderness, or induration (most common; typically resolves within 24–48 hours)
Transient fatigue or mild flu-like sensation in first 1–2 days of a new cycle (uncommon)
GI discomfort with oral formulations — rare; typically resolves with food co-administration
Theoretical concern for promoting growth in pre-existing undetected neoplastic tissue — screen appropriately before initiating
No known drug-drug interactions reported in available literature; exercise clinical judgment when combining with DMARDs or immunosuppressants

6.3 Monitoring Recommendations

Baseline joint assessment: VAS pain score, functional mobility testing, imaging (X-ray ± MRI) for OA staging
Reassessment at 4–6 weeks during initial treatment cycle and at cycle completion
Annual imaging in patients with moderate-to-severe OA to assess cartilage space
Monitor for injection site reactions; rotate sites systematically
Baseline inflammatory markers (CRP, ESR) in patients with inflammatory arthropathy; repeat at 3-month intervals
Screen for active infection or malignancy prior to initiating any peptide bioregulator protocol
Periodic review of concomitant medications, particularly anticoagulants (injection-site consideration) and immunomodulators

Legal Disclaimer

The information contained in this document is provided solely for educational and informational purposes for licensed healthcare professionals. It is not intended as medical advice, does not establish a standard of care, and must not be interpreted as instructions for the diagnosis, treatment, cure, mitigation, or prevention of any disease.

Cartalax (Ala-Glu-Asp), and other peptides referenced herein are not FDA-approved drugs. Their clinical use, including oral, subcutaneous, topical, or injectable administration, may constitute off-label or investigational use. Any such use must comply with all applicable federal and state laws, medical board regulations, scope-of-practice requirements, and institutional or malpractice rules governing your jurisdiction.

Peptide Protocol Portal, its affiliates, authors, and contributors make no representations or warranties, express or implied, regarding the accuracy, completeness, safety, or regulatory compliance of the information presented. Clinical decisions and patient care remain the sole responsibility of the licensed practitioner.

Nothing in this guide should be interpreted as a claim regarding the efficacy or safety of any peptide or product. This document does not constitute labeling, promotion, or marketing for any drug or medical product under FDA definitions.

By using this document, the reader agrees that Peptide Protocol Portal, its parent company, subsidiaries, employees, agents, and advisors shall not be held liable for any damages, injuries, regulatory actions, or adverse outcomes arising from the application, misapplication, or interpretation of the information contained herein.

Use at your own risk. Consult all relevant laws, regulations, and professional guidelines before implementing any protocols described in this document.

References — Cartalax Clinical Reference Guide

Peptide Bioregulator Research — Khavinson Laboratory

1. Khavinson, V. Kh., & Morozov, V. G. Peptides of pineal gland and thymus prolong human life. Neuro Endocrinology Letters, 24(3–4), 233–240 (2003).

2. Khavinson, V. Kh., et al. Short peptide bioregulators for the correction of age-related changes in tissues. Bulletin of Experimental Biology and Medicine, 151(1), 115–119 (2011).

3. Khavinson, V. Kh., et al. Peptide regulation of gene expression: a systematic review. Molecules, 28(4), 1549 (2023).

Chondroprotection & Cartilage Matrix Biology

4. Loeser, R. F., et al. Osteoarthritis: a disease of the joint as an organ. Arthritis & Rheumatism, 64(6), 1697–1707 (2012).

5. Buckwalter, J. A., & Mankin, H. J. Articular cartilage: degeneration and osteoarthritis, repair, regeneration, and transplantation. Instructional Course Lectures, 47, 487–504 (1998).

6. Goldring, M. B., & Goldring, S. R. Articular cartilage and subchondral bone in the pathogenesis of osteoarthritis. Annals of the New York Academy of Sciences, 1192, 230–237 (2010).

Epigenetic Mechanisms of Peptide Bioregulation

7. Vanyushin, B. F., & Khavinson, V. Kh. Short biologically active peptides as epigenetic modulators of gene activity. Biochemistry (Moscow), 72(11), 1571–1577 (2007).

8. Khavinson, V. Kh., et al. Peptide epigenetic regulators: novel tools for tissue regeneration and longevity. Frontiers in Genetics, 11, 612 (2020).

Inflammation & MMP Activity in Osteoarthritis

9. Bondeson, J., et al. The role of synovial macrophages and macrophage-produced cytokines in driving aggrecanases, cartilage degradation, and other destructive factors in osteoarthritis. Arthritis Research & Therapy, 12(1), R57 (2010).

10. Troeberg, L., & Nagase, H. Proteases involved in cartilage matrix degradation in osteoarthritis. Biochimica et Biophysica Acta, 1824(1), 133–145 (2012).

Chondrocyte Apoptosis & Cell Survival

11. Hwang, H. S., & Kim, H. A. Chondrocyte apoptosis in the pathogenesis of osteoarthritis. International Journal of Molecular Sciences, 16(11), 26035–26054 (2015).

12. Mobasheri, A., et al. The role of metabolism in the pathogenesis of osteoarthritis. Nature Reviews Rheumatology, 13(5), 302–311 (2017).

Bioregulator Peptide Clinical Outcomes & Longevity

13. Anisimov, V. N., et al. Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice. Biogerontology, 4(4), 193–202 (2003).

14. Kuznik, B. I., et al. Bioregulatory peptides: prospects for use in gerontology and regenerative medicine. Advances in Gerontology, 25(2), 200–209 (2012).

Combination Regenerative Approaches

15. Siebert, C. H., et al. Regenerative approaches to cartilage repair: current status and future directions. Knee Surgery, Sports Traumatology, Arthroscopy, 17(11), 1376–1382 (2009).

16. Kon, E., et al. Platelet-rich plasma intra-articular injection versus hyaluronic acid viscosupplementation as treatments for cartilage pathology. Arthroscopy, 27(11), 1490–1501 (2011).